{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.472","value":"0.726"},{"groupId":"OG001","spread":"1.690","value":"0.779"}]}],"title":"Non-Study Medical Visits"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.718","value":"0.279"},{"groupId":"OG001","spread":"0.656","value":"0.312"}]}],"title":"Telephone Consultations"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.273","value":"0.402"},{"groupId":"OG001","spread":"2.187","value":"0.562"}]}],"title":"Hospital Days"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.156","value":"0.037"},{"groupId":"OG001","spread":"0.195","value":"0.067"}]}],"title":"ER Visits"}],"denoms":[{"counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Non-study medical visits were defined as the sum of primary care physician visits, nurse practitioner/physician's assistant/nurse visits, and medical or surgical specialist visits. Days hospitalized were defined as the sum of days in the general ward and days in intensive care. The number of telephone consultations and ER visits was assessed via individual questions on the electronic Case Report Form. The endpoint was totaled through Week 24, divided by the number of days on treatment for each participant, then multiplied by 30 days to get the number of visits per 30 days.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Only those participants who had non-study medical visits, telephone consultations, days in the hospital, and ER visits were analyzed.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to Week 24","title":"Mean Number of Non-study Medical Visits, Telephone Consultations, Hospital Days, and Emergency Room (ER) Visits Per 30 Days Through Week 24","type":"SECONDARY","unitOfMeasure":"events per 30 days"}